In line with prior studies in patients with cardiovascular disease (59), treatment of mice with rivaroxaban reduced the frequency of CD41+ monocyte-platelet aggregates that also stained positive for LAP and GARP (Figure 5, A and C). Here, TGFB1 is linked to cardiovascular disorder.